Key result
HeartMate 3 LVAD enables discharge home and improves quality of life at 3 months in LGMD.
Why the study?
Advanced heart failure therapies such as durable ventricular assist device implantation are infrequently used in patients with muscular dystrophy due to comorbid impairments in mobility and respiratory function.
Case Report (n=1)
No
Carefully selected pediatric patients with muscular dystrophy and severe cardiomyopathy may benefit from durable LVAD implantation.
No takes yet. Share an insight, caveat, or question.
Supports feasibility of VAD or transplant in select muscular dystrophy cardiomyopathy; leaves open broader applicability and long-term outcomes.
Zumwalt et al. (2025) conducted a case report in Limb-girdle muscular dystrophy type R4 with chronic decompensated heart failure (n=1). HeartMate 3 left ventricular assist device was evaluated on Clinical recovery and discharge. Implantation of a HeartMate 3 left ventricular assist device in a 16-year-old male with limb-girdle muscular dystrophy type R4 and severe heart failure resulted in successful discharge home and substantial improvements in quality of life at 3 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: